Peter Guzzo
Corporate Officer/Principal at TRYPTAMINE THERAPEUTICS LIMITED
Peter Guzzo active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TRYPTAMINE THERAPEUTICS LIMITED | Corporate Officer/Principal | 22/12/2020 | - |
Career history of Peter Guzzo
Former positions of Peter Guzzo
| Companies | Position | Start | End |
|---|---|---|---|
| ALBANY MOLECULAR RESEARCH, INC. | Corporate Officer/Principal | 01/01/1996 | 01/01/2015 |
ConSynance Therapeutics, Inc.
 ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Chief Executive Officer | 01/03/2015 | - |
| Founder | 01/03/2015 | - |
Training of Peter Guzzo
| University of Notre Dame | Doctorate Degree |
| Assumption College | Undergraduate Degree |
Statistics
International
| United States | 5 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Tryp Therapeutics, Inc.
 Tryp Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada. | Health Technology |
ConSynance Therapeutics, Inc.
ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Health Technology |
Curia Global, Inc.
 Curia Global, Inc. BiotechnologyHealth Technology Curia Global, Inc. engages in drug research and development, and manufacturing. It offers drug delivery, drug development, analytical services, API development and manufacturing, and drug product solutions. The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY. | Health Technology |
- Stock Market
- Insiders
- Peter Guzzo
- Experience
